Skip to main content

IRB Barcelona opens new laboratory focused on targeted protein degradation as a therapeutic tool




Press & Communications Section Head
Tel.+34 93 40 37255

Scientist Cristina Mayor-Ruiz joins IRB Barcelona to lead the “Targeted Protein Degradation and Drug Discovery” laboratory.

With this new group, IRB Barcelona now has 27 laboratories and 8 scientific platforms.

Along with the addition of the new laboratory, the Institute is also launching a Drug Screening Unit devoted to drug discovery.

Researcher Cristina Mayor-Ruiz (Soria, 1989), who is forging a career in cancer research and is an expert on targeted protein degradation, joins IRB Barcelona to lead a new laboratory. The Targeted Protein Degradation and Drug Discovery lab will apply the novel technique of targeted protein degradation to the molecular study of diseases such as cancer and the discovery of new therapeutic approaches.

Targeted protein degradation is based on a cell degradation process discovered by Aaron Ciechanover, Avram Hershko and Irwin Rose and awarded with the Nobel Prize in Chemistry in 2004. This technique uses different types of "degrading" drugs to bring a target protein (for example, a mutated protein that contributes to the development of a disease) closer to the cellular machinery that directs protein degradation. By forcing these two components together, target proteins are labelled for destruction by the cell proteasome.

"Currently, about 80% of all proteins in our body cannot be reached by traditional drugs," explains Cristina Mayor-Ruiz, "my lab aims to organise the discovery and generation of new degrading drugs in such a way as to cover a much wider range of proteins and thus offer more therapeutic  opportunities."


PROTACs, molecular glues and accessible "cavities"

Traditionally, drug discovery has been limited to proteins with accessible "cavities" that could be targeted to inhibit them. The targeted protein degradation technique seeks to overcome this limitation by working with two types of degrading drugs that bring target proteins closer to the cellular machinery that directs degradation. PROTACs (or PROteolysis TArgeting Chimeras) are drugs with two binders: one binds to the target protein and the other recruits the cellular machinery that directs degradation. Molecular glues, on the other hand, although performing the same function, have only one module, thereby hindering their rational design.  Collections of thousands of compounds known as “drug libraries” emerge as the best way to identify these glues.

To support this new line of research, and other projects already underway, IRB Barcelona has launched a drug discovery unit. The unit will be guided by a drug development plan, thereby reflecting a clear commitment to speeding up the transfer of basic research to clinical practice


From biotechnology to biological chemistry, with oncology as a goal

Cristina Mayor-Ruiz holds a degree in Biotechnology from the University of Salamanca. She did her PhD in Molecular Biology in Oscar Fernández-Capetillo’s laboratory, at the Spanish National Council Research Center (CNIO), where she focused on mechanisms of resistance to cancer therapies. She later joined Georg Winter's laboratory as a postdoctoral researcher at the Research Center for Molecular Medicine (CeMM) in Vienna, Austria.

"After my time at CNIO, with the same enthusiasm and wishing to have a more direct impact on cancer treatment, I decided to do a postdoc in chemical biology. I was fascinated by the potential of targeted protein degradation as a drug discovery strategy and I joined the group of one of the leading experts in the field," says Mayor-Ruiz.

Her work has led to 8 scientific articles, 5 of them as first author, including articles in journals such as Nature Chemical Biology and Molecular Cell.


Awardee of the I FERO-ASEICA Grant

Today (Friday 6 November) Cristina Mayor-Ruiz has received the I FERO-ASEICA Grant, in the context of the XVII ASEICA International Congress. This grant provides €80,000 for the cancer research project to be developed at IRB Barcelona. The FERO-ASEICA Cancer Research Grant supports young scientific talent and helps develop new avenues of cancer research that can be transferred to patients.


IRB Barcelona's commitment to young talent

Securing the services of Mayor-Ruiz is part of the centre's commitment to recruiting top talent and offer leadership opportunities to young scientists.

"IRB Barcelona is one of the best centres in Europe," says Mayor-Ruiz, "it is very exciting to have the opportunity to work with people who I greatly admire and to have the opportunity to use the extensive cutting-edge facilities". "I have trained with relatively young group leaders and I believe that in many respects it is an added value, so I hope that other young researchers place their trust in me and join me on this adventure," she adds.

The laboratory headed by Mayor-Ruiz will initially have two PhD students, a postdoctoral researcher and a laboratory technician. With the addition of this new group, IRB Barcelona has 27 laboratories and 8 technological platforms.


About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).